drugset / Trial / NCT03758404
Gene Therapy for Achromatopsia (CNGA3)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A clinical trial of adeno-associated virus vector (AAV) CNGA3 retinal gene therapy for patients with achromatopsia
Timeline
- Start
- 2019-08-12
- Primary completion
- 2021-06-10
- Completion
- 2021-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGURACINGENE CADOPARVOVEC | Gene therapy (AAV / viral vector) | — | Other |